Social media

In today’s fast-evolving drug development landscape, regulatory affairs is no longer a back-office function—it’s a strategic pillar at the boardroom table. Therefore Pharma leaders must understand and consider how to nav...

In today’s fast-evolving drug development landscape, regulatory affairs is no longer a back-office function—it’s a strategic pillar at the boardroom table. Therefore Pharma leaders must understand and consider how to n...

How do you choose the right control group for organ impairment trials? Despite consensus on the need for demographic similarity between test and control groups, practical guidance is surprisingly scarce. Too often, sele...

Join ICON for “Science on Tap” — an evening of discovery, discussion, and holiday cheer! Explore cutting-edge research in precision medicine and bioanalytical laboratory innovation with our expert scientists. If you ar...

Join ICON for “Science on Tap” — an evening of discovery, discussion, and holiday cheer! Explore cutting-edge research in precision medicine and bioanalytical laboratory innovation with our expert scientists. If you ar...

Join Rose Kidd, President of Operations Delivery, on 6 December at SCDM India for the closing keynote exploring how patients, sites and technology are redefining clinical research. The session will examine how evolving ...

Congress attendance is expensive, and arrangements are time consuming. Use Journals & Congresses to make decisioning faster and easier with 50+ data fields to compare options and make the most of your attendance. Request...

Congress attendance is expensive, and arrangements are time consuming. Use Journals & Congresses to make decisioning faster and easier with 50+ data fields to compare options and make the most of your attendance. Request...

DHTs promise faster, more inclusive trials, but they must be implemented correctly. ICON’s latest whitepaper is a must-read for organizations looking to deploy digital measures in their trials. The whitepaper offers step...

For the third and final article in our series, ICON’s regulatory expert Jeremy Tinkler discusses ISO 10993-1 in the context of risk estimation. This article looks at the upcoming revision of ISO 10993-1, which has spar...

For the third and final blog in our series, we discuss ISO 10993-1 in the context of risk estimation. This blog looks at the upcoming revision of ISO 10993-1, which has sparked debate but now is in its final draft stag...

Patient recruitment strategies need to evolve to ensure the best data from a wider range of patients. Meet ICON experts at #ASH25, booth \#2161 to learn how our strategic solutions and innovative methods help reduce pati...